| Name | Title | Contact Details |
|---|
CerFlux Personalized Medicine aims to reduce the pain, reduce the discomfort, and reduce the cost of cancer treatment.
healthchemdiagnostics is a Pompano Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Ultivue develops innovative reagent-based solutions that maximize the biological information available from cells and tissue samples. The company`s technology is being used to elucidate biological pathways and to validate clinically-relevant biomarkers. Ultivue is based in Cambridge, MA. Our culture provides an exceptional work environment fostering innovation and collaboration to make a difference collectively. Ultivue`s employees are bright, flexible, and driven to create meaningful impact through our work. We work at a fast pace, but support each other achieve the work/life balance that helps us thrive as a company. Our entrepreneurial culture relies on contributions and input from all. Our bench of experienced managers provides mentoring and support to ensure front line staff make the most of their unique talents and energy.
Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington`s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.